Progress in the application of microtubulin inhibitors in prostate cancer
- VernacularTitle:微管蛋白抑制剂在前列腺癌中的应用进展
- Author:
Nan GUO
1
;
Baokai DOU
1
;
Jing ZHANG
1
Author Information
1. Dept. of Pharmacy，Provincial Hospital Affiliated to Shandong First Medical University，Jinan 250021，China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
metastatic castration-resistant prostate cancer;
microtubule inhibitors;
docetaxel;
combination
- From:
China Pharmacy
2025;36(13):1683-1688
- CountryChina
- Language:Chinese
-
Abstract:
When prostate cancer （PCa） progresses to the metastatic castration-resistant stage， significant challenges arise in clinical treatment. Microtubulin inhibitors have become first-line drugs for the treatment of metastatic castration-resistant PCa due to their unique mechanism of action. Among them， taxanes （e.g. docetaxel and cabazitaxel） remain standard care with proven survival benefits， while other microtubule inhibitors （e.g. vincristine， colchicine） show limited clinical utility due to toxicity. Currently， the clinical approach primarily employs docetaxel-based triple therapy and combined with immune checkpoint inhibitors to improve the prognosis of PCa patients， reverse the immunosuppressive state of the tumor microenvironment， and enhance therapeutic efficacy. Despite the remarkable clinical efficacy of microtubule inhibitors in the treatment of PCa， the emergence of drug resistance has limited their long-term application. To address this issue， researchers have explored new solutions， including the development of novel microtubule inhibitors in combination with ATP-binding cassette subfamily B member 1 inhibitors， the concurrent use of fatty acid synthase inhibitors with microtubule inhibitors， and the development of degraders based on proteolysis-targeting chimeras technology. Future research should focus on target discovery， drug formulation optimization， and personalized approaches to overcome current therapeutic limitations.
